Truist Financial’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.6M | Buy |
7,044
+3,430
| +95% | +$611K | ﹤0.01% | 1505 |
|
|
2026
Q1 | $623K | Sell |
3,614
-760
| -17% | -$141K | ﹤0.01% | 1943 |
|
|
2025
Q4 | $873K | Sell |
4,374
-64
| -1% | -$11.6K | ﹤0.01% | 1738 |
|
|
2025
Q3 | $694K | Sell |
4,438
-2,818
| -39% | -$448K | ﹤0.01% | 1845 |
|
|
2025
Q2 | $1.1M | Sell |
7,256
-23,542
| -76% | -$3.14M | ﹤0.01% | 1553 |
|
|
2025
Q1 | $4.64M | Buy |
30,798
+856
| +3% | +$144K | 0.01% | 866 |
|
|
2024
Q4 | $5.53M | Sell |
29,942
-4,250
| -12% | -$819K | 0.01% | 785 |
|
|
2024
Q3 | $6.73M | Sell |
34,192
-3,032
| -8% | -$630K | 0.01% | 719 |
|
|
2024
Q2 | $7.69M | Sell |
37,224
-2,761
| -7% | -$626K | 0.01% | 691 |
|
|
2024
Q1 | $10.8M | Sell |
39,985
-970
| -2% | -$232K | 0.02% | 599 |
|
|
2023
Q4 | $9.68M | Sell |
40,955
-1,106
| -3% | -$218K | 0.02% | 626 |
|
|
2023
Q3 | $8.24M | Buy |
42,061
+1,255
| +3% | +$258K | 0.01% | 646 |
|
|
2023
Q2 | $8.58M | Sell |
40,806
-527
| -1% | -$105K | 0.01% | 640 |
|
|
2023
Q1 | $8.34M | Buy |
41,333
+1,038
| +3% | +$235K | 0.01% | 641 |
|
|
2022
Q4 | $8.78M | Buy |
40,295
+570
| +1% | +$124K | 0.02% | 616 |
|
|
2022
Q3 | $7.82M | Buy |
39,725
+2,281
| +6% | +$492K | 0.02% | 643 |
|
|
2022
Q2 | $8.01M | Sell |
37,444
-2,096
| -5% | -$512K | 0.01% | 651 |
|
|
2022
Q1 | $11.2M | Buy |
39,540
+5,085
| +15% | +$1.57M | 0.02% | 605 |
|
|
2021
Q4 | $13M | Buy |
34,455
+1,144
| +3% | +$444K | 0.02% | 556 |
|
|
2021
Q3 | $13.7M | Buy |
33,311
+1,384
| +4% | +$575K | 0.02% | 527 |
|
|
2021
Q2 | $11.8M | Buy |
31,927
+2,117
| +7% | +$707K | 0.02% | 578 |
|
|
2021
Q1 | $8.64M | Buy |
29,810
+1,555
| +6% | +$432K | 0.02% | 645 |
|
|
2020
Q4 | $7.06M | Sell |
28,255
-161
| -0.6% | -$38.3K | 0.01% | 709 |
|
|
2020
Q3 | $6.43M | Sell |
28,416
-4,132
| -13% | -$858K | 0.01% | 679 |
|
|
2020
Q2 | $5.67M | Sell |
32,548
-5,216
| -14% | -$832K | 0.01% | 697 |
|
|
2020
Q1 | $4.77M | Sell |
37,764
-387
| -1% | -$58K | 0.01% | 690 |
|
|
2019
Q4 | $5.83M | Buy |
38,151
+13,448
| +54% | +$1.86M | 0.01% | 705 |
|
|
2019
Q3 | $3.27M | Sell |
24,703
-574
| -2% | -$77K | 0.06% | 283 |
|
|
2019
Q2 | $3.59M | Sell |
25,277
-1,193
| -5% | -$162K | 0.06% | 263 |
|
|
2019
Q1 | $3.85M | Sell |
26,470
-145
| -0.5% | -$19.1K | 0.07% | 256 |
|
|
2018
Q4 | $3.01M | Buy |
26,615
+444
| +2% | +$55.6K | 0.06% | 274 |
|
|
2018
Q3 | $3.52M | Sell |
26,171
-956
| -4% | -$118K | 0.06% | 280 |
|
|
2018
Q2 | $3.04M | Sell |
27,127
-2,004
| -7% | -$217K | 0.06% | 302 |
|
|
2018
Q1 | $3.11M | Sell |
29,131
-1,965
| -6% | -$212K | 0.06% | 294 |
|
|
2017
Q4 | $3.4M | Sell |
31,096
-642
| -2% | -$69.9K | 0.06% | 287 |
|
|
2017
Q3 | $3.43M | Buy |
+31,738
| New | +$3.26M | 0.07% | 282 |
|
Other funds holding CRL
CB
BTW
CIM
RP
JPMIA
Truist Financial's CRL Position: Q2 2026 in Review
Truist Financial increased its Charles River Laboratories (CRL) stake by 95% in Q2 2026, buying an estimated $611K and bringing the position to 7,044 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1505.
Truist Financial first reported a position in CRL in Q3 2017 and has held it in 36 quarters since. The position peaked at $13.7M in Q3 2021. 173 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Truist Financial held 7,044 shares of Charles River Laboratories worth $1.6M as of Q2 2026.
- Truist Financial bought 3,430 Charles River Laboratories shares in Q2 2026, an estimated $611K.
- Charles River Laboratories made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #1505 holding.
- Truist Financial first reported a position in Charles River Laboratories in Q3 2017 and has held it in 36 quarters since.
- Truist Financial's Charles River Laboratories position peaked at $13.7M in Q3 2021.
- 173 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.